Brief: Hyloris: Partnership With Hikma For U.S. Commercialisation Of Maxigesic IV

Hyloris Pharmaceuticals SA

28/04/2021 06:49

April 28 (Reuters) - HYLORIS PHARMACEUTICALS SA  HYL.BR :
    * HYLORIS ANNOUNCES MAJOR COMMERCIAL PARTNERSHIP IN THE U.S.
FOR
MAXIGESIC® IV WITH HIKMA PHARMACEUTICALS  HIK.L 
    * IS ELIGIBLE TO RECEIVE $4 MLN IN REGULATORY BASED
MILESTONES AS
WELL AS COMMERCIAL MILESTONES AND A SHARE OF NET PROFIT
    * TO COMMERCIALISE MAXIGESIC IV IN U.S.
    * MAXIGESIC IV HAS POTENTIAL TO COMBAT OPIOID EPIDEMIC IN
PAIN
MANAGEMENT

Source text for Eikon:  ID:nGNE466hHp 
Further company coverage:  HYL.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00 ;))